{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:27:35Z","timestamp":1794432455123,"version":"4.9.1"},"reference-count":23,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100019531","name":"Apellis Pharmaceuticals, Inc.","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100019531","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To evaluate the efficacy of intravitreal (IVT) pegcetacoplan monthly vs avacincaptad pegol monthly (primary analysis), and pegcetacoplan every other month vs avacincaptad pegol monthly (secondary analysis), for geographic atrophy (GA).\n                    <jats:bold>Methods:<\/jats:bold>\n                    Matching-adjusted indirect comparisons were conducted across global phase 3 trials using individual patient data from 2 pegcetacoplan trials (OAKS, NCT03525613; DERBY, NCT03525600) and published aggregate data from the avacincaptad pegol GATHER2 trial (NCT04435366). GATHER2 inclusion and exclusion criteria were applied to the OAKS and DERBY individual patient data. Key baseline variables were balanced using propensity score weighting. GA lesion growth at month 12 was assessed. Results from the matching-adjusted indirect comparisons were combined using meta-analysis.\n                    <jats:bold>Results:<\/jats:bold>\n                    The primary analysis included 103 patients from OAKS and 102 patients from DERBY who met the GATHER2 inclusion and exclusion criteria and 447 patients from GATHER2. In OAKS vs GATHER2, the adjusted difference in GA lesion growth at month 12 between pegcetacoplan monthly and avacincaptad pegol was \u22120.716 mm\n                    <jats:sup>2<\/jats:sup>\n                    (95% CI, \u22121.385 to \u22120.046;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u2009.04), statistically favoring pegcetacoplan monthly. In DERBY vs GATHER2, the adjusted difference was \u22120.234 mm\n                    <jats:sup>2<\/jats:sup>\n                    (95% CI, \u22121.354 to 0.885;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u2009.68), directionally favoring pegcetacoplan monthly. After meta-analysis, the pooled effect for pegcetacoplan monthly vs avacincaptad pegol was \u22120.589 mm\n                    <jats:sup>2<\/jats:sup>\n                    (95% CI, \u22121.164 to \u22120.014;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u20090.04), statistically favoring pegcetacoplan monthly. A numerically greater reduction in GA lesion growth was observed with pegcetacoplan every other month vs avacincaptad pegol monthly (95% CI, \u22121.130 to \u22120.300;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2009=\u2009.25).\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Matching-adjusted indirect comparisons support a greater reduction in GA growth with pegcetacoplan monthly vs avacincaptad pegol monthly and no significant difference between pegcetacoplan every other month and avacincaptad pegol monthly.\n                  <\/jats:p>","DOI":"10.1177\/24741264251379842","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T07:27:35Z","timestamp":1760686055000},"page":"46-56","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of Intravitreal Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy"],"prefix":"10.1177","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6574-388X","authenticated-orcid":false,"given":"Paul","family":"Hahn","sequence":"first","affiliation":[{"name":"NJ Retina, Teaneck, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0654-0668","authenticated-orcid":false,"given":"David","family":"Eichenbaum","sequence":"additional","affiliation":[{"name":"Retina Vitreous Associates of Florida, St. Petersburg, FL, USA"},{"name":"Morsani College of Medicine, University of South Florida, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilsher S.","family":"Dhoot","sequence":"additional","affiliation":[{"name":"California Retinal Consultants\/Retina Consultants of America, Santa Barbara, CA, USA"},{"name":"Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-5091","authenticated-orcid":false,"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[{"name":"Retina Consultants of Texas, Retina Consultants of America, Houston, TX, USA"},{"name":"Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Klufas","sequence":"additional","affiliation":[{"name":"Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Intorcia","sequence":"additional","affiliation":[{"name":"Apellis Pharmaceuticals, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Jones","sequence":"additional","affiliation":[{"name":"Apellis Pharmaceuticals, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata P.","family":"Sarda","sequence":"additional","affiliation":[{"name":"Apellis Pharmaceuticals, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Bobbili","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Chang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryaline","family":"Catillon","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyi","family":"Xu","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirthana","family":"Sarathy","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R.","family":"Baumal","sequence":"additional","affiliation":[{"name":"Apellis Pharmaceuticals, Waltham, MA, USA"},{"name":"New England Eye Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9988-4146","authenticated-orcid":false,"given":"Varun","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"Department of Surgery, McMaster University, Hamilton, ON, Canada"},{"name":"Hamilton Regional Eye Institute, St. Joseph\u2019s Healthcare Hamilton &amp; Hamilton Health Sciences, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.08.038"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01520-9"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.02.031"},{"issue":"7","key":"e_1_3_3_5_2","first-page":"1500","article-title":"Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies","volume":"63","author":"Goldberg R","year":"2022","unstructured":"Goldberg R, Heier JS, Wykoff CC, et al Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies. Invest Ophthalmol Vis Sci. 2022;63(7):1500.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.08.027"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01583-0"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01298-x"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.22005"},{"key":"e_1_3_3_10_2","unstructured":"Phillippo D Ades T Dias S Palmer S Abrams KR Welton N. NICE DSU Technical Support Document 18: Methods for Population-Adjusted Indirect Comparisons in Submissions to NICE. NICE Decision Support Unit; 2016."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100936"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13138"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029073"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-023-06531-8"},{"issue":"8","key":"e_1_3_3_17_2","first-page":"4196","article-title":"Investigating nAMD and DME treatment burden on recipients and caregivers in the US","volume":"64","author":"Watane A","year":"2023","unstructured":"Watane A, Tabano D, Cox O, et al Investigating nAMD and DME treatment burden on recipients and caregivers in the US. Invest Ophthalmol Vis Sci. 2023;64(8):4196.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-016-3384-0"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272301"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.copsyc.2015.03.004"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-7563.2011.01400.x"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1106934"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462319000333"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8759"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251379842","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264251379842","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251379842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:25:53Z","timestamp":1790695553000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264251379842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/24741264251379842"],"URL":"https:\/\/doi.org\/10.1177\/24741264251379842","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}